Kunming Longjin Pharmaceutical Co Ltd
Kunming Longjin Pharmaceutical Co., Ltd. therapeutic medicines for people living with cardiovascular, cerebrovascular, and metabolic diseases in China. The company offers medicines in the areas of cardiovascular and cerebrovascular, digestive system, vitamin, minerals and enteral nutrition, and immunology, as well as first aid kits; extracts of natural plants, such as breviscapine; and industrial… Read more
Kunming Longjin Pharmaceutical Co Ltd (002750) - Total Liabilities
Latest total liabilities as of March 2025: CN¥69.96 Million CNY
Based on the latest financial reports, Kunming Longjin Pharmaceutical Co Ltd (002750) has total liabilities worth CN¥69.96 Million CNY as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kunming Longjin Pharmaceutical Co Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Kunming Longjin Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Kunming Longjin Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Kunming Longjin Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Riverview Rubber Estates Bhd
KLSE:2542
|
Malaysia | RM44.17 Million |
|
Lippo Cikarang Tbk
JK:LPCK
|
Indonesia | Rp4.50 Trillion |
|
Hyprop
JSE:HYP
|
South Africa | ZAC16.26 Billion |
|
PT Black Diamond Resources Tbk
JK:COAL
|
Indonesia | Rp463.17 Billion |
|
Air Industries Group
NYSE MKT:AIRI
|
USA | $39.11 Billion |
|
Gumho NT Co Ltd
KQ:130500
|
Korea | ₩97.64 Billion |
|
Partner Tech Corp.
TWO:3097
|
Taiwan | NT$1.04 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Kunming Longjin Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kunming Longjin Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kunming Longjin Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual total liabilities of Kunming Longjin Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥80.19 Million | -11.41% |
| 2023-12-31 | CN¥90.51 Million | -36.46% |
| 2022-12-31 | CN¥142.44 Million | -4.39% |
| 2021-12-31 | CN¥148.99 Million | +8.71% |
| 2020-12-31 | CN¥137.05 Million | -2.80% |
| 2019-12-31 | CN¥141.00 Million | +7.13% |
| 2018-12-31 | CN¥131.62 Million | -5.78% |
| 2017-12-31 | CN¥139.69 Million | +56.56% |
| 2016-12-31 | CN¥89.22 Million | -10.28% |
| 2015-12-31 | CN¥99.45 Million | -33.71% |
| 2014-12-31 | CN¥150.02 Million | +6.72% |
| 2013-12-31 | CN¥140.57 Million | -0.39% |
| 2012-12-31 | CN¥141.11 Million | +40.24% |
| 2011-12-31 | CN¥100.62 Million | -- |